Cargando…

Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality

Influenza vaccination is proven effective in preventing influenza. However, long-term effects on mortality have never been supported by direct evidence. In this study we assessed the long-term outcome of influenza vaccination on mortality in the elderly by conducting a 25-year follow-up study of a R...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhees, Ruud Andreas Fritz, Thijs, Carel, Ambergen, Ton, Dinant, Geert Jan, Knottnerus, Johannes Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532873/
https://www.ncbi.nlm.nih.gov/pubmed/31120943
http://dx.doi.org/10.1371/journal.pone.0216983
_version_ 1783421079129161728
author Verhees, Ruud Andreas Fritz
Thijs, Carel
Ambergen, Ton
Dinant, Geert Jan
Knottnerus, Johannes Andreas
author_facet Verhees, Ruud Andreas Fritz
Thijs, Carel
Ambergen, Ton
Dinant, Geert Jan
Knottnerus, Johannes Andreas
author_sort Verhees, Ruud Andreas Fritz
collection PubMed
description Influenza vaccination is proven effective in preventing influenza. However, long-term effects on mortality have never been supported by direct evidence. In this study we assessed the long-term outcome of influenza vaccination on mortality in the elderly by conducting a 25-year follow-up study of a RCT on the efficacy of influenza vaccination as baseline. The RCT had been conducted in the Netherlands 5 years before vaccination was recommended for those aged >65 and 17 years before recommending it for those aged >60. The RCT included 1838 community-dwelling elderly aged ≥ 60 that had received an intramuscular injection with the inactivated quadrivalent influenza vaccine (n = 927) or placebo (n = 911) during the 1991/1992 winter. In our follow-up study, outcomes included all-cause mortality, influenza-related mortality and seasonal mortality. Unadjusted and adjusted hazard ratios (HRs) were estimated by Cox regression and sub-hazard ratios (SHRs) by competing risk models. Secondary analyses included subgroup analyses by age and disease status. The vital status up to January 1, 2017 was provided in 1800/1838 (98%) of the cases. Single influenza vaccination did not reduce all-cause mortality when compared to placebo (adjusted HR 0.95, 95% CI 0.85−1.05). Also, no differences between vaccination and placebo group were shown for underlying causes of death or seasonal mortality. In those aged 60–64, median survival increased with 20.1 months (95% CI 2.4–37.9), although no effects on all-cause mortality (adjusted HR 0.86, 95% CI 0.72−1.03) could be demonstrated in survival analysis. In conclusion, this study did not demonstrate a statistically significant effect following single influenza vaccination on long-term mortality in community-dwelling elderly in general. We propose researchers designing future studies on influenza vaccination in the elderly to fit these studies for longer-term follow-up, and suggest age-group comparisons in observational research. Clinical trial registry number: NTR6179.
format Online
Article
Text
id pubmed-6532873
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65328732019-06-05 Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality Verhees, Ruud Andreas Fritz Thijs, Carel Ambergen, Ton Dinant, Geert Jan Knottnerus, Johannes Andreas PLoS One Research Article Influenza vaccination is proven effective in preventing influenza. However, long-term effects on mortality have never been supported by direct evidence. In this study we assessed the long-term outcome of influenza vaccination on mortality in the elderly by conducting a 25-year follow-up study of a RCT on the efficacy of influenza vaccination as baseline. The RCT had been conducted in the Netherlands 5 years before vaccination was recommended for those aged >65 and 17 years before recommending it for those aged >60. The RCT included 1838 community-dwelling elderly aged ≥ 60 that had received an intramuscular injection with the inactivated quadrivalent influenza vaccine (n = 927) or placebo (n = 911) during the 1991/1992 winter. In our follow-up study, outcomes included all-cause mortality, influenza-related mortality and seasonal mortality. Unadjusted and adjusted hazard ratios (HRs) were estimated by Cox regression and sub-hazard ratios (SHRs) by competing risk models. Secondary analyses included subgroup analyses by age and disease status. The vital status up to January 1, 2017 was provided in 1800/1838 (98%) of the cases. Single influenza vaccination did not reduce all-cause mortality when compared to placebo (adjusted HR 0.95, 95% CI 0.85−1.05). Also, no differences between vaccination and placebo group were shown for underlying causes of death or seasonal mortality. In those aged 60–64, median survival increased with 20.1 months (95% CI 2.4–37.9), although no effects on all-cause mortality (adjusted HR 0.86, 95% CI 0.72−1.03) could be demonstrated in survival analysis. In conclusion, this study did not demonstrate a statistically significant effect following single influenza vaccination on long-term mortality in community-dwelling elderly in general. We propose researchers designing future studies on influenza vaccination in the elderly to fit these studies for longer-term follow-up, and suggest age-group comparisons in observational research. Clinical trial registry number: NTR6179. Public Library of Science 2019-05-23 /pmc/articles/PMC6532873/ /pubmed/31120943 http://dx.doi.org/10.1371/journal.pone.0216983 Text en © 2019 Verhees et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Verhees, Ruud Andreas Fritz
Thijs, Carel
Ambergen, Ton
Dinant, Geert Jan
Knottnerus, Johannes Andreas
Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
title Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
title_full Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
title_fullStr Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
title_full_unstemmed Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
title_short Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
title_sort influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. no impact on long-term mortality
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532873/
https://www.ncbi.nlm.nih.gov/pubmed/31120943
http://dx.doi.org/10.1371/journal.pone.0216983
work_keys_str_mv AT verheesruudandreasfritz influenzavaccinationintheelderly25yearsfollowupofarandomizedcontrolledtrialnoimpactonlongtermmortality
AT thijscarel influenzavaccinationintheelderly25yearsfollowupofarandomizedcontrolledtrialnoimpactonlongtermmortality
AT ambergenton influenzavaccinationintheelderly25yearsfollowupofarandomizedcontrolledtrialnoimpactonlongtermmortality
AT dinantgeertjan influenzavaccinationintheelderly25yearsfollowupofarandomizedcontrolledtrialnoimpactonlongtermmortality
AT knottnerusjohannesandreas influenzavaccinationintheelderly25yearsfollowupofarandomizedcontrolledtrialnoimpactonlongtermmortality